Business Interruption Risk from Disasters, Accidents and Pandemics
First written in FY2016. 9 of 17 entries say "Restated". Latest entry: FY2026.
Mochida Pharmaceutical moved to the "Worse" side of this theme in 2020, the same year as the typical company in this theme.
The whole theme swung hardest in 2020: 67 of 114 companies on the "Worse" side.
101 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「If large-scale natural disasters or other disasters or accidents cause serious impacts or damage to the group's factories, research facilities, branches and other business locations, including the shutdown or failure of information systems, or if the spread of infectious diseases causes business activities to stagnate or factories to cease operations, resulting in product shortages or other issues, they may materially affect operating results and financial condition.」
The company has reconfirmed the risks of business interruption and product shortages due to disasters, accidents, information system shutdowns and infectious diseases, as well as responses through BCP and a stable supply system. - FY2025RestatedAnnual report
「If large-scale natural disasters or other disasters or accidents cause serious impacts or damage to the group's factories, research facilities, branches and other business locations, including the shutdown or failure of information systems, or if the spread of infectious diseases causes business activities to stagnate or factories to cease operations, resulting in product shortages or other issues, they may materially affect operating results and financial condition.」
The company has reconfirmed the risks of business interruption and product shortages due to disasters, accidents, information system shutdowns and infectious diseases, as well as mitigation measures through BCP and a stable supply system. - FY2023-Q3RestatedAnnual report
「The impact of COVID-19 on business performance was limited.」
The company continues to state that the impact of COVID-19 was limited. - FY2023-Q2RestatedAnnual report
「The impact of COVID-19 on business performance was limited.」
Although COVID-19 continued, the company states that its impact on second-quarter business performance was limited. - FY2023-Q1RestatedAnnual report
「The impact of COVID-19 on business performance was limited.」
Although COVID-19 continued, the company states that its impact on business performance during the quarter was limited. - FY2022MitigatedAnnual report
「Although some impact from the spread of COVID-19 was seen in business activities, its impact on sales and profit for the consolidated fiscal year was immaterial.」
Although delays in patient enrollment and other issues occurred in some areas, there were no significant events in the manufacturing supply chain, and the company states that the impact on full-year sales and profit was immaterial. - FY2022-Q3RestatedAnnual report
「The impact of COVID-19 on business performance was limited.」
Although COVID-19 continued, the company states that its impact on third-quarter business performance was limited. - FY2022-Q2RestatedAnnual report
「The impact of COVID-19 on business performance was limited.」
Although COVID-19 continued, the company states that its impact on second-quarter business performance was limited. - FY2022-Q1MitigatedAnnual report
「The impact of COVID-19 on business performance was limited.」
Although COVID-19 continued, the company states that its impact on first-quarter business performance was limited. - FY2021MaterialisedAnnual report
「In research and development, some projects have experienced delays in patient enrollment and the addition of clinical trial sites, but overall progress remains broadly on plan. In pharmaceutical manufacturing, no significant events have occurred in the supply chain for active pharmaceutical ingredients and formulations.」
Although delays in patient enrollment and other effects of COVID-19 occurred in some projects, the company states that no significant event occurred in the manufacturing supply chain. - FY2021-Q3MaterialisedAnnual report
「The business was affected by drug price revisions in October 2019 and April 2020, as well as by reduced medical consultations due to COVID-19 and medical representatives (MRs) refraining from visiting medical institutions.」
The impact of COVID-19 continued to appear in the pharmaceuticals-related business during the third quarter as reduced medical consultations and MRs refraining from visiting medical institutions. - FY2021-Q2MaterialisedAnnual report
「The pharmaceuticals-related business was affected by drug price revisions in October 2019 and April 2020, as well as by reduced medical consultations due to COVID-19 and medical representatives (MRs) refraining from visiting medical institutions.」
The impact of COVID-19 appeared in business activities as reduced medical consultations and MRs refraining from visiting medical institutions. - FY2021-Q1MaterialisedAnnual report
「The cosmetics market remains sluggish due to people refraining from going out and other factors related to COVID-19. Meanwhile, demand for hygiene-related products such as cleansing soaps has increased.」
The impact of COVID-19 appeared as market changes, namely a sluggish cosmetics market and increased demand for hygiene-related products. - FY2020MaterialisedAnnual report
「As of the filing date, the impact of COVID-19 on business performance was limited. In research and development, some projects have experienced delays in patient enrollment, but there have been no major changes to the plans.」
The pandemic occurred in reality, resulting in delays in patient enrollment in some projects. The company states that no significant event affecting product supply occurred. - FY2019RestatedAnnual report
「At each of the group's factories, research facilities, branches and other business locations, the company is promoting various measures, including the development of business continuity plans, in preparation for disasters or accidents such as earthquakes and pandemics. However, if large-scale natural disasters or other disasters, accidents or pandemics cause business activities to stagnate or factories to cease operations, they may materially affect operating results and financial condition.」
The company has reiterated the risk of business interruption due to disasters, accidents or pandemics while proceeding with measures including business continuity plans. - FY2018RestatedAnnual report
「At each of the group's factories, research facilities, branches and other business locations, the company is promoting various measures, including the development of business continuity plans, in preparation for disasters or accidents such as earthquakes and pandemics. However, if large-scale natural disasters or other disasters, accidents or pandemics cause business activities to stagnate or factories to cease operations, they may materially affect operating results and financial condition.」
The company has reiterated the risk of business interruption due to disasters, accidents or pandemics while proceeding with measures including business continuity plans. - FY2016First statedAnnual report
「If large-scale natural disasters or other disasters, accidents or pandemics cause business activities to stagnate or factories to cease operations, they may materially affect operating results and financial condition.」
Although the company is promoting measures including the development of business continuity plans, the risk was described as a residual risk.